15 results about "Placenta Growth Factor" patented technology

The invention discloses a micro-fluidic photoelectrochemical immunosensor based on a ZnIn2S4-In2S3 heterojunction photosensitive material and application of the micro-fluidic photoelectrochemical immunosensor based on the ZnIn2S4-In2S3 heterojunction photosensitive material, synthesized In2S3 is used as a precursor, and the ZnIn2S4-In2S3 heterojunction photosensitive material is synthesized in one step. A ZnIn2S4-In2S3 heterojunction photosensitive material is sprayed on the tin oxyfluoride electrode subjected to photoetching of the micro-fluidic channel, and an ascorbic acid solution is used as a solution for enhancing a light absorption signal; the preparation method comprises the following steps: preparing a placenta growth factor monoclonal antibody, activating amino and carboxyl of the sensor through chitosan (CTS) and glutaraldehyde (GA), and fixing the placenta growth factor monoclonal antibody on a heterojunction photosensitive material through a covalent bond to obtain the microfluidic photoelectrochemical immunosensor. And the kit has good clinical sample detection capability and has important clinical application value for human precision medical research.

The present disclosure relates to a modified fusion proteins in which a vascular endothelial growth factor is associated with a placental growth factor, and a use thereof. The modified fusion protein according to an embodiment of the present disclosure can exhibit excellent productivity and stability. The modified fusion protein according to an embodiment of the present disclosure can also demonstrate excellent blood stability. The modified fusion protein according to an embodiment of the present disclosure, compared to conventionally developed substances, possesses acidic properties and can show an increased ratio of charge isoforms in the acidic and neutral regions of the pI distribution.

A polypeptide complex, a protein, a nucleic acid, a composition and uses thereof. A cell specific high expression and long retention (ePR) strategy is employed to overexpress specific mRNA in hepatic stellate cells into therapeutic proteins and to promote long-term anchoring of the therapeutic proteins in a fibrotic matrix microenvironment. The first-generation and second-generation retinol derivatives containing carboxyl are determined, can partially replace cholesterol in lipoid nanoparticles (LNP), and are enriched in a fibrosis area through intravenous injection, so that the expression of mRNA in a fibrosis liver is improved by about 10 times. Furthermore, therapeutic mRNA has been engineered by coupling the gene sequence of the collagen binding domain (CBD) to the C-terminus of the therapeutic protein. In screening, it is found that the peptide sequence of placental growth factor (PLGF) shows the strongest collagen affinity, the liver residence time of overexpressed therapeutic protein can be prolonged, and systemic side effects are reduced to the minimum.

Provided according to one aspect of the present disclosure is a composition for wound healing or tissue regeneration that comprises a genomic DNA fragment extracted from human placenta-derived mesenchymal stem cells and a placental growth factor and which exhibits excellent tissue regeneration ability. Provided according to another aspect of the present disclosure is a preparation method which enables the efficient, biocompatible, economical, and environmentally friendly production of a composition for wound healing or tissue regeneration having excellent tissue regeneration ability.

The invention develops a construction method of a novel preeclampsia prediction model based on insulin growth binding factor binding protein 1 (IGFBP1) and placental growth factor (PlGF) and related application of the novel preeclampsia prediction model. Specifically, according to the method, IGFBP1 and / or PLGF of a pregnant woman, clinical information and MAP data serve as input, whether the pregnant woman suffers from preeclampsia or not serves as output, model construction is conducted through a machine learning method, and a preeclampsia prediction model is obtained. As effective detection can be carried out only by adopting one or two protein predictive markers without depending on the uterine artery pulsation index, the cost is low, and on the whole, clinical popularization is more convenient, the medical expenditure is reduced, the mom and infant outcome is effectively improved, and the method has important significance on reducing the mortality rate of pregnant and lying-in women and infants.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The present disclosure relates to a modified fusion proteins in which a vascular endothelial growth factor is associated with a placental growth factor, and a use thereof. The modified fusion protein according to an embodiment of the present disclosure can exhibit excellent productivity and stability. The modified fusion protein according to an embodiment of the present disclosure can also demonstrate excellent blood stability. The modified fusion protein according to an embodiment of the present disclosure, compared to conventionally developed substances, possesses acidic properties and can show an increased ratio of charge isoforms in the acidic and neutral regions of the pI distribution.

The present disclosure relates to modified fusion proteins that bind to vascular endothelial growth factor and placenta growth factor, and uses thereof. The modified fusion proteins according to one embodiment of the present disclosure can exhibit excellent productivity and stability. The modified fusion proteins according to one embodiment of the present disclosure can exhibit excellent stability in blood. The modified fusion proteins according to one embodiment of the present disclosure have acidic properties compared to previously developed substances, and can exhibit an increased ratio of charge variants in the acidic and neutral regions of the pI distribution.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

This invention provides a method for identifying patients suitable for T-cell therapy, or a method for preparing patients to be suitable for T-cell therapy. [Solution] A method is provided for treating cancer in a patient suitable for T-cell therapy, comprising the steps of (i) administering to a patient one or more preconditioning agents having the ability to increase serum levels of at least one additional cytokine selected from the group consisting of interleukin-15, interleukin-7, and monocyte chemotactic protein 1, C-reactive protein, placental growth factor, interferon-gamma-inducible protein 10, and any combination thereof; and (ii) having the patient undergo T-cell therapy.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.

The present invention discloses a low-threshold potential electrochemiluminescence immunosensor, a preparation method thereof and an application thereof, which relate to the field of biological detection. It includes a three-electrode system, and the three-electrode system includes a working electrode, a reference electrode and a counter electrode. The working electrode includes: a conductive substrate; a vertically ordered mesoporous silica thin film formed on the surface of the conductive substrate, and the vertically ordered mesoporous silica thin film has nanochannels; gold-copper alloy nanoparticles formed in the nanochannels; an epoxy group modification layer formed on the outer surface of the vertically ordered mesoporous silica thin film; a placental growth factor specific antibody covalently bound to the epoxy group modification layer; bovine serum albumin covalently bound to the region on the epoxy group modification layer that is not bound by the placental growth factor specific antibody. The present invention has the advantages of being able to achieve efficient electrochemiluminescence at a low potential and improving the detection sensitivity and stability.

The invention relates to the technical field of biological detection, and particularly discloses a placental growth factor and soluble fms-like tyrosine kinase-1 joint detection kit and application thereof. The placenta growth factor and soluble fms-like tyrosine kinase-1 joint detection kit comprises a sample pad, a combination pad, a coating film, a water absorption pad and a sample diluent, the coating film is an NC film coating antibody; the preparation method of the conjugate pad comprises the following steps: treating the fiber membrane with a pretreatment solution, drying, and then spraying the time-resolved fluorescent microsphere labeled antibody. The placenta growth factor and soluble fms-like tyrosine kinase-1 are jointly detected by using the detection kit and the detection method provided by the invention, and the sensitivity, the accuracy and the repeatability are relatively high.

Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and / or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

The present disclosure relates to a modified fusion protein in which a vascular endothelial growth factor is associated with a placental growth factor, and uses thereof. The modified fusion protein according to an embodiment of the present disclosure can exhibit excellent productivity and stability. The modified fusion proteins according to embodiments of the present disclosure may also exhibit excellent blood stability. The modified fusion proteins according to embodiments of the present disclosure have acidic properties compared to conventionally developed materials and can exhibit an increased proportion of charge isoforms in the acidic and neutral regions of the pI distribution.